Accurate diagnosis and customized treatment are ongoing challenges in modern healthcare. Conventional approaches to managing diseases can fail to give doctors the precise information they need to customize treatment plans for each patient. This disparity in the way healthcare is provided can jeopardize patient outcomes and highlight the urgent need for innovative diagnostic approaches.

Castle Biosciences, driven by a desire to improve patient care, provides proprietary laboratory tests that are designed to improve the way diseases are managed. Castle is at the leading edge of personalized medicine and is dedicated to advancing the healthcare industry through innovation and improving health outcomes for patients. With a portfolio encompassing six commercially available tests addressing skin cancers (melanoma and squamous cell carcinoma), Barrett’s oesophagus, mental health conditions, and uveal melanoma, Castle’s goal is to advance precision and excellence in personalized medicine.

Established in 2008 by Derek Maetzold, President and CEO, Castle Biosciences emerged from a vision to revolutionize cancer care by leveraging genomic insights to tailor treatment strategies. Alongside co-founders Toby Juvenal, Chief Commercial Officer, and Kristen Oelschlager, Chief Operating Officer, Maetzold pioneered a paradigm shift in disease management, placing patients’ needs at the forefront of Castle’s mission.

Castle specializes in proprietary laboratory-developed tests designed to provide personalized, clinically actionable information. These tests empower clinicians and patients to make more informed treatment decisions, with the goal of improving patient outcomes. Castle works to ensure that its solutions are reliable and effective by constantly adding to the body of evidence that backs up its tests. In 2023 alone, the company collaborated with leading researchers in their fields to produce the publication of 23 peer-reviewed studies validating the performance characteristics of its tests.

Castle’s flagship test, DecisionDx-Melanoma, exemplifies its commitment to advancing cancer diagnostics. Supported by 50 peer-reviewed publications and extensive studies involving over 10,000 patients, DecisionDx-Melanoma has demonstrated a tangible association with improved patient survival—a testament to Castle’s unwavering dedication to enhancing clinical outcomes.

Castle has been recognized for its outstanding achievements in the healthcare arena. With its commitment to creating a strong company culture, driving innovation, and delivering high-quality performance, it has earned numerous prestigious awards, including being named to the Top Workplaces USA list for three consecutive years (2022, 2023 and 2024) and securing recognition as a Top Workplace in the Healthcare Industry in 2023. Castle Biosciences has also been honored as a Top Workplace by the Houston Chronicle for three consecutive years (2021, 2022 and 2023) and has earned similar acclaim as a Top Workplace in Arizona, according to AZ Central (2022 and 2023).

The company’s leadership and strategic prowess were acknowledged by Inc.’s Best-Led Companies of 2021.  Castle has also been celebrated for its groundbreaking contributions to oncology and dermatology through several MedTech Breakthrough Awards, winning distinctions such as “Best New Technology Solution for Oncology” in 2021 and “Best New Technology Solution – Dermatology” in 2022. In 2023, the company’s innovative application of artificial intelligence in healthcare was recognized with yet another MedTech Breakthrough Award for the “Best Use of Artificial Intelligence in Healthcare.”The culmination of Castle Biosciences’ remarkable growth and success was marked by the prestigious AZBio Fast Lane Award in 2022, underscoring its position as a trailblazer in the industry. Castle’s leadership credits its success to its exceptional employees. “None of our achievements would be possible without the hard work and strong execution of the entire Castle team, and I can’t thank them enough,” Maetzold commented during a recent company earnings call.

In line with its growth strategy, Castle has thoughtfully expanded its portfolio through strategic acquisitions, marking pivotal moments in the company’s history. In 2021, the acquisitions of MyPath® Melanoma, and Cernostics and the TissueCypher® Barrett’s Esophagus test heralded significant strides in expanding the company’s diagnostic portfolio. The subsequent year it included another strategic acquisition, the IDgenetix® test. The growth momentum continued in 2023, as Castle Biosciences unveiled a new laboratory in Pittsburgh. The expansion enhanced the company’s operational capabilities and reaffirmed its commitment to advancing diagnostic excellence.

Acquiring technologies like the TissueCypher and IDgenetix tests, Castle has diversified its offerings from dermatology and uveal melanoma to encompass complementary markets in gastroenterology and mental health.

The executive leadership team at Castle Biosciences comprises seasoned industry experts dedicated to driving innovation and fostering a culture of excellence. Led by Derek Maetzold, the team includes Frank Stokes (Chief Financial Officer), Kristen Oelschlager (Chief Operating Officer), Toby Juvenal (Chief Commercial Officer), Bob Cook, Ph.D. (Senior Vice President, Research & Development), Alice Izzo (Senior Vice President, Marketing), and Matthew Goldberg, M.D. (Senior Vice President, Medical).

Ever resolute in utilizing personalized diagnostics to transform disease management, Castle Biosciences remains steadfast in its commitment to ultimately improve patient outcomes.